TY  - JOUR

T1  - MP11-13 CLINICAL FRACTURE INCIDENCE IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (mHSPC) AND RISK-REDUCTION FOLLOWING ADDITION OF ZOLEDRONIC ACID TO ANDROGEN DEPRIVATION THERAPY (ADT) WITH OR WITHOUT DOCETAXEL (DOC): LONG-TERM RESULTS FROM 2 PHASE 3 TRIALS FROM THE STAMPEDE PLATFORM PROTOCOL

JO  - Journal of Urology

UR  - https://doi.org/10.1097/ju.0000000000003226.13

PY  - 2023/04/01

AU  - Jones C

AU  - Sachdeva A

AU  - Murphy L

AU  - Murray M

AU  - Brown L

AU  - McCloskey E

AU  - Brown J

AU  - Attard G

AU  - Parmar M

AU  - James N

AU  - Sydes M et al

ED  - 

DO  - DOI: 10.1097/ju.0000000000003226.13

PB  - Ovid Technologies (Wolters Kluwer Health)

VL  - 209

IS  - Supplement 4

Y2  - 2026/06/24

ER  -